EUCTR2021-000905-26-SE
Active, not recruiting
Phase 1
Immune response to Covid-19 vaccination in patients with immune modulatory treatment for cancer - CoVaCan
Department of Oncology, Uppsala University Hospita0 sites150 target enrollmentMarch 12, 2021
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Immune response to Covid-19 vaccination of patients with immune modulatory treatment for cancer
- Sponsor
- Department of Oncology, Uppsala University Hospita
- Enrollment
- 150
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 years or older
- •Treatment for cancer within 6 month with CD20\-depleting therapy and/or check\-point inhibitors and/or chemotherapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 50
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 100
Exclusion Criteria
- •Unable to give informed consent
- •Subject is not eligible to receive Covid\-19 vaccine according to current reccommendations from the Public Health Agency of Sweden.
- •Subject has a known hypersensitivity to the active substance or to any of the components of the investigational medical product, as specified in the product’s Summary of Product Characteristics, SmPC .
- •Estimated life expectancy of less than three months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Immune response to COVID-19 Vaccination in people with Diabetes MellitusType 1 Diabetes MellitusType 2 Diabetes MellitusTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2021-001459-15-ATMedical University of Graz161
Active, not recruiting
Phase 1
COVID-19 vaccine induced immune response in patients with primary antibody deficiencyCOVID-19Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2021-004891-33-FITurku University Hospital50
Active, not recruiting
Phase 1
Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 .Renal failure stage 4 and 5.Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2021-000988-68-SERegion Stockholm60
Recruiting
Phase 4
Antibody response to COVID-19 vaccination in immunosuppressed patients with autoimmune diseaseRheumatoid arthritisPsoriatic arthritisAnkylosing spondylitisCrohn's DiseaseUlcerative ColitisCOVID-19Inflammatory bowel diseaseInflammatory and Immune System - Autoimmune diseasesOral and Gastrointestinal - Crohn's diseaseOral and Gastrointestinal - Inflammatory bowel diseaseMusculoskeletal - Other muscular and skeletal disordersInfection - Other infectious diseasesInflammatory and Immune System - Other inflammatory or immune system disordersInflammatory and Immune System - Rheumatoid arthritisACTRN12621000661875Dr Ai Tran100
Not yet recruiting
Not Applicable
COVID-19 vaccination of vulnerable populations (COVULPOP)COVID-19 vaccine responseCOVID-19Inflammatory and Immune System - Normal development and function of the immune systemRespiratory - Other respiratory disorders / diseasesInfection - Other infectious diseasesACTRN12621001492842Prof Katie Flanagan40